{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:23:59Z","timestamp":1787239439893,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["19H03874"],"award-info":[{"award-number":["19H03874"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80549-1","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T22:08:23Z","timestamp":1735855703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data"],"prefix":"10.1038","volume":"15","author":[{"given":"Akira","family":"Shinohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikatsu","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"80549_CR1","unstructured":"Foundation for Promotion of Cancer Research. Cancer Statistics in Japan-2022 (Foundation for Promotion of Cancer Research, 2022). https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2022.pdf"},{"key":"80549_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/MPA.0b013e3181bd6489","volume":"39","author":"MK Lau","year":"2010","unstructured":"Lau, M. K., Davila, J. A. & Shaib, Y. H. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39, 458\u2013462 (2010).","journal-title":"Pancreas"},{"key":"80549_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"80549_CR4","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"80549_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","volume":"81","author":"M Ozaka","year":"2018","unstructured":"Ozaka, M. et al. A phase II study of modified folfirinox for chemotherapy-na\u00efve patients with metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 81, 1017\u20131023 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"80549_CR6","unstructured":"National Comprehensive Cancer Network [NCCN guideline]. Pancreatic Adenocarcinoma. version 2.2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"key":"80549_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MPA.0000000000001513","volume":"49","author":"T Okusaka","year":"2020","unstructured":"Okusaka, T. et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas 49, 326\u2013335 (2020).","journal-title":"Pancreas"},{"key":"80549_CR8","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40273-018-0684-8","volume":"36","author":"M Gharaibeh","year":"2018","unstructured":"Gharaibeh, M. et al. Economic evaluation for the UK of systemic chemotherapies as first-line treatment of metastatic pancreatic cancer. Pharmacoeconomics 36, 1333\u20131343 (2018).","journal-title":"Pharmacoeconomics"},{"key":"80549_CR9","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1007\/s00520-019-4659-x","volume":"27","author":"M de Mol","year":"2019","unstructured":"de Mol, M. et al. Frequency of low-grade adverse events and quality of life during chemotherapy determine patients\u2019 judgement about treatment in advanced-stage thoracic cancer. Support. Care Cancer 27, 3563\u20133572 (2019).","journal-title":"Support. Care Cancer"},{"key":"80549_CR10","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","volume":"30","author":"A Gu\u00e9rin","year":"2014","unstructured":"Gu\u00e9rin, A. et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr. Med. Res. Opin. 30, 2317\u20132328 (2014).","journal-title":"Curr. Med. Res. Opin."},{"key":"80549_CR11","doi-asserted-by":"crossref","unstructured":"Schaefer, A. J., Bailey, M. D., Shechter, S. M. & Roberts, M. S. Modeling medical treatment using Markov decision processes. In Operations Research and Health Care (eds Brandeau, M. L., Sainfort, F. & Pierskalla, W. P.) 593\u2013612 (Springer, (2005).","DOI":"10.1007\/1-4020-8066-2_23"},{"key":"80549_CR12","unstructured":"Woods, B. et al. DSU technical support. Partitioned Survival Analysis for Decision Modelling in Healthcare: A Critical Review. NICE Decision Support Unit, Document 19 (2017). https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD19-Partitioned-Survival-Analysis-final-report.pdf"},{"key":"80549_CR13","unstructured":"Center for Outcomes Research and Economic Evaluation for Health. Overview of cost-effectiveness evaluation system in Japan (2019). https:\/\/c2h.niph.go.jp\/tools\/system\/overview_en.pdf"},{"key":"80549_CR14","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal (Natl Inst. for Health and Care Excellence, London, 20132013) (NICE) [Internet]. Process and Methods Guides No. 9."},{"key":"80549_CR15","unstructured":"Statistics Bureau Japan. Statistical handbook of Japan 2021. Data Is Available by 5 Years of Age (2021). http:\/\/www.stat.go.jp\/data\/nihon\/02.html, Tables 2\u201320."},{"key":"80549_CR16","unstructured":"Ministry of Health. Labour and Welfare (dirs)-general for statistics and information policy. Vital statistics of Japan 2019. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/houkoku19\/dl\/all.pdf"},{"key":"80549_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13561-023-00418-x","volume":"13","author":"Y Takumoto","year":"2023","unstructured":"Takumoto, Y. et al. Health state utility values for metastatic pancreatic cancer using a composite time trade-off based on the vignette-based approach in Japan. Health Econ. Rev. 13, 3 (2023).","journal-title":"Health Econ. Rev."},{"key":"80549_CR18","unstructured":"Japan Clinical Oncology Group. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03 (2010). http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv4J_20170912_v20_1.pdf"},{"key":"80549_CR19","unstructured":"Japan Clinical Oncology Group. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (2017). http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv5J_20210901_v24_1.pdf"},{"key":"80549_CR20","unstructured":"Various information of medical fee. The master record of medical service compensation in FY2021 revision. https:\/\/shinryohoshu.mhlw.go.jp\/shinryohoshu\/kaitei\/doKaiteiR04\/"},{"key":"80549_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa, T. et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 19, 422\u2013437 (2010).","journal-title":"Health Econ."},{"key":"80549_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-7547-11-22","volume":"11","author":"T Shiroiwa","year":"2013","unstructured":"Shiroiwa, T., Igarashi, A., Fukuda, T. & Ikeda, S. WTP for a QALY and health states: more money for severer health states? Cost Eff. Resour. Alloc. 11, 22 (2013).","journal-title":"Cost Eff. Resour. Alloc."},{"key":"80549_CR23","first-page":"27","volume":"68","author":"T Fukuda","year":"2019","unstructured":"Fukuda, T. & Shiroiwa, T. Application of economic evaluation of pharmaceuticals and medical devices in Japan. J. Natl. Inst. Public Health 68, 27\u201333 (2019).","journal-title":"J. Natl. Inst. Public Health"},{"key":"80549_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/13696998.2016.1269015","volume":"20","author":"M Gharaibeh","year":"2017","unstructured":"Gharaibeh, M., McBride, A., Bootman, J. L., Patel, H. & Abraham, I. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus folfirinox versus gemcitabine in the treatment of metastatic pancreas cancer. J. Med. Econ. 20, 345\u2013352 (2017).","journal-title":"J. Med. Econ."},{"key":"80549_CR25","doi-asserted-by":"crossref","unstructured":"Zhou, J. et al. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori 294\u2013300 (2016).","DOI":"10.5301\/tj.5000499"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80549-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T21:03:00Z","timestamp":1735938180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["80549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80549-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted with the approval of the ethics committee of the National Cancer Center Hospital East (NCCHE) and the need to obtain informed consent was waived by the committee. The study was conducted in accordance with epidemiological research guidelines (2019\u2009\u2212\u2009179). This hospital makes research proposals approved by the IRB available to the public. For studies utilizing medical information without obtaining an ICF, patients can access a PDF summary of the research and opt out of participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"267"}}